Biotech Seminar Archive

04/29/2009	Nicholas Wade Author and Reporter The New York Times The Faith Instinct – How religion evolved and why it endures
04/15/2009	Noah Weisleder, PhD Co-founder and Chief Scientific Officer TRIM-edicine, Inc. ProteinTherapeutics in Regenerative Medicine
04/08/2009	Brendan Rauw, MBA Portfolio Director Science and Technology Ventures, Columbia University University-Industry Alliances in Life Sciences
04/01/2009	Imtiaz Mawji, PhD Consultant Datamonitor Healthcare Consulting The Role of Concurrent design in Guiding Strategic Decisions in the Pharmaceutical Industry
03/25/2009	Daniel Yarosh Senior Vice President Basic Science Research, The Estee Lauder CoMAies Biotechnology: Going to Market
03/11/2009	Alan Morrison, JD Partner Cohen Pontani Lieberman & Pavane, LLP Understanding the Biotechnology Patent
03/04/2009	Daniel Ferrara, MA Biotechnology Criminalist Office of the Chief Medical Examiner, NY City Forensic DNA Testing: Science serving Justice
02/18/2009	Robert Tillman, PhD Director, Science Alliance The New York Academy of Sciences The Roles of Non-profits in Advancing Science and Innovation
04/23/2008	Jamie Li, PhD Director, Urology/Gynecology R/D Boston Scientific The Practical Part of Biotechnology
04/16/2008	Michael A. Davitz, MD, JD Partner Axinn, Veltrop & Harkrider LLP The Role of Intellectual Property in the Pharmaceutical and Biotechnology Environment
04/09/2008	Aseem Anand, MA Biotechology Clinical Trial Coordinator, MSKCC, and Founder, BioTrak Organizational Issues in Biotech
04/02/2008	David Best, MD, MBA, and Michael Banks, MD President and Vice President MDea, Inc. Careers in Medical Communication and Big Pharma
03/26/2008	Alan E. Smith, PhD Senior Vice President, Research, Chief Scientific Officer Genzyme Corp Therapies for Genetic Diseases
03/12/2008	David Sable, MD Fund Manager Special Situations Life Sciences Fund Investing in Biotechnology: Inside a Life Sciences Hedge Fund
03/05/2008	Michael Rice Senior Consultant Defined Health Cardiovascular Franchises: Too Much Risk in Prevention?
02/27/2008	Greg Homison, PhD Director of Research and Technical Services Department of Biological Sciences Infrastructure: From the Mechanical to the Interpersonal
02/20/2008	Angelos M. Stergiou, MD VP Product Development, Medical Affairs & Clinical Research Accentia Biopharmaceuticals Treating and Curing Patients, Clinical Research and Development
02/13/2008	Daijin Kim, MBA Associate Director, Healthcare Informatics Pfizer Human Health Challenges & Opportunities in the Pharmaceutical Industry
04/25/2007	Ross Grossman, PhD, MBA VP, Human Resources Regeneron Pharmaceuticals, Inc. Organizational Issues in Biotech
04/11/2007	Ivica Labuda Founder and President Biokeys for Flavors, LLC Biotechnology Role in Flavor Industry
04/04/2007	Kelly Wines, MA Biotechology Associate Fitzpatrick, Cella, Harper & Scinto Intellectual Property: Where Technology Meets the Law
03/28/2007	Jerry Di Salvo Distinguished Senior Research Associate, Department of Immunology Merck Research Laboratories A View from the Bench: Basic Research and Drug Development
03/21/2007	Melanie Rolli, MD Director, Brand Safety Leader, Integrated Medical Safety Novartis Pharmaceuticals Corporation From Bench to Bedside: The Process and the People that Turn an Idea into a Drug
03/07/2007	Vivien Marx Science Writer The Art of Describing Science to the World
02/28/2007	Chau Cheng, PhD Associate Director, Investor Relations and Business Analysis ImmunoMedics Investor Relations in the Biotech sector. What is unique about it?
02/14/2007	Nelson Scharadin, MA Biotechology Investment Banker Healthcare Investment Banking, Oppenheimer & Co Falling forward in the business of Biotechnology
02/07/2007	Heather Butts Regulatory Specialist Institutional Review Board, ColumbiaUniversity Bringing it all together: issues in research ethics, history and review
04/26/2006	Gary Shangold, MD President & Managing Member Convivotech, LLC. Creating Your Own Career in the Life Sciences
04/19/2006	Ron Guido and Alan McEmber Directors, Worldwide Regulatory Strategy Pfizer Pitfall Avoidance: Regulatory Affairs as Tactician in Biotechnology Product Development
04/05/2006	Eugene Trogan, PhD Biotechnology Analyst Ursus Capital Management Biotech and the Savvy Investor: How to Stay with the Good and part with the Bad
03/29/2006	Thierry Teil, MD Executive Director The Medicines Company Pharma and Biotech Industry: Overview & Opportunities for Biology Graduates
03/22/2006	Steve Dinh, Sc.D. Vice President, Research and Technology Development Emisphere Oral Delivery of Protein Therapeutic Molecules
03/08/2006	Eliene Augenbraun, DO, PhD CEO and President ScienCentral, Inc. Bite Size Biotech – how most Americans learn about science
03/01/2006	Philip Braginsky, JD Of Counsel Sills Cummis Epstein and Gross The Commercial Realm of Patents
02/15/2006	Holly Hilton, PhD Research Informatics, Genetics and Genomics Hoffmann-La Roche Inc. The Role of Functional Genomics in Drug Discovery
02/10/2006	Marie Teil, MD Director, Clinical Trials Office Mount Sinai School of Medicine Drug Approval Process -from an FDA perspective or from a pharma point of view
02/08/2006	Jeff Yablon Principal Yablon Management Consulting/PharmaScan Clinical Trials, LLC. Introduction to Clinical Development & Biotech Management Concepts
02/01/2006	Lata Jayaraman, PhD Senior Research Investigator Bristol-Myers Squibb Choosing a Career in the Bio-Pharmaceutical Industry
04/27/2005	William Fair, MA VP, Healthcare & Biosciences New York City Economic Development Corp. Commercial Bioscience in New York
04/20/2005	Josh Xiao, PhD Sr. Scientist Amgen San Francisco High Throughput Screening in the Functional Genomics Era
04/13/2005	Ivan Oransky, MD Deputy Editor The Scientist Biotechnology and the Media
04/06/2005	Costa Papastephanou, PhD President and COO Ortec International The Anatomy of a Biotech CoMAy
03/30/2005	Linda Armstrong, MD Medical Director Pfizer Assessing Drug Safety: From Bench to Blockbuster
03/23/2005	Mark Kay, MD, PhD Director, Human Gene Therapy Program Stanford University Gene Transfer Strategies for Treating Hemophilia and Viral Hepatitis
03/09/2005	Allen Fienberg, PhD Founder & VP, Business Development Intra-Cellular Therapies Reflections on the Transition froMAadeMAto Corporate Life
03/02/2005	Michael Yamin, PhD Director, Technology Development Warren Pharmaceuticals, Inc. Tissue Protective Cytokines from Discovery to Development
02/23/2005	Jeff Margolis President Aurora Capital LLC Start-up and Early Stage Biotechnology CoMAies: Translating Science into Products
02/16/2005	Charles Ryan, PhD, JD Executive Director, Chief Patent Counsel Forest Laboratories, Inc. The Role of Intellectual Property in Pharmaceutical Drug Development
04/21/2004	Eelco A. Slagter, MS Director of Science and Technology AMDeC Foundation, inc. Developments in the Biosciences: An Integrative Approach
04/14/2004	Ramana Sonty, MBBS, PhD Senior Director, Worldwide Development Pfizer Integrated R&D/Commercial Cross-Functional Approaches to Strategy, Portfolio and Risk
04/07/2004	Rene Baston, MA and Matthew McCooe, MBA Associate Directors ColumbiaUniversity Science and Technology Ventures Technology Transfer - Making an IMAt
03/31/2004	Sundeep Bhan President and CEO Medsite, Inc. Exploring Entrepreneurial Opportunities in Biotechnology
03/24/2004	Nicholas Giorgio, PhD Senior Director of Protein Sciences ImClone Systems, Inc. A Brief History of Erbitux, from the Lab Bench to Aapproval and Beyond
03/10/2004	Melanie Rolli, MD Associate Director, Clinical Research Novartis Pharmaceuticals From Bench to Bedside: The Process and the People that Turn an Idea into a Drug
03/03/2004	Mary Morry, PhD, JD Senior Attorney, Intellectual Property Litigation Merck & Co. Patents and Practical Tips for Obtaining and Using Them
02/25/2004	Ilya Trakht, D. Sc. Chief Research Consultant Acceptys Totally Human Antibodies: from Bench Science to Biotech Business
02/11/2004	David Sudolsky, MBA Principal Sudco Consulting Adventures of a Serial Biotech Entrepreneur
02/04/2004	David Weinstein, PhD, MD President and Chief Scientific Officer GliaMed Inc. Biology-based Drug Discovery in the Nervous System
01/28/2004	Charles Jennings, PhD Executive Editor Nature Research Journals The Role of Journals in the Communication of Science
04/23/2003	Louis J. Capezzuto, JD, MA Biotechology Patent Law Department Johnson & Johnson Biotechnology Patents 101- The Basics
04/16/2003	Uwe Scherf, PhD Director, R & D Gene Logic Whole Genome Expression Profiling: Generating and Utilizing High Quality Data
04/09/2003	Nezih Cereb, MD Executive VP and co-founder Histogenetics, Inc. Clinical Implications of Polymorphism of the Human MHC (Major HistocoMAibilty Complex) Genes--Industrialization of Molecular Tissue Typing
04/02/2003	Don O’Sullivan, PhD Senior Account Executive Euro RSCG Life NRP Communicating Biotechnology-the value of public and investor relations in the life sciences industry
03/26/2003	Rene Baston, MA and Matthew McCooe, MBA Associate Directors Columbia University Science and Technology Ventures Technology Transfer from Academia
03/12/2003	Tina Lopingo, PhD Director, Technology and Business Development New York Biotechnology Association New York’s Biotechnology Landscape
03/05/2003	Julie Kan, PhD Senior Research Investigator OSI Pharmaceuticals The ‘omics’ World for Small Molecule Cancer Drug Discovery
02/26/2003	Bharat Mehta, PhD VP Manufacturing Operations Genta, Inc. Regulatory Requirements in Pharmaceutical Manufacturing with Focus on Critical Utilities and BSE/TSE-Viral Safety
02/19/2003	Andrew Marshall, PhD Editor Nature Biotechnology The Vision of Genomics and the Reality in Drug Development
02/12/2003	Timothy Howe, MBA Partner Collinson Howe & Lennox Medical Partners Venture Capital in the Biotechnology Space
02/05/2003	Rudolph Spangler, PhD Senior Research Associate Rockefeller University Designing an Efficient High Throughput Gene Expression Technology
01/29/2003	M. Timothy Cooke, PhD MBA CEO Mojave Therapeutics Creating Value: Business Models in Biotechnology
05/01/2002	Anthony J. Russo, PhD CEO and General Manager Noonan/ Russo Public Relationship in Biotechnology
04/24/2002	Hillel Cohen, PhD Director, Drug Regulatory Affairs Novartis Pharmaceutical Corporation The Role of Regulatory Affairs in Development of Biopharmaceuticals.
04/17/2002	Kenneth H. Sonnenfeld, PhD Partner Morgan and Finnegan The Swinging Pendulum of Biotechnology Patent Law: What’s patenable and What’s Not
04/10/2002	Robert Crowl, PhD Novartis Pharmaceuticals Corporation Genomics and Drug Target Discovery Facing the Challenge of Osteoarthritis
04/03/2002	Frank Carrigan, PhD, Beth S. Kauderer, PhD, JD, Mathew McCooe, MBA Director and Associate Directors ColumbiaUniversity Science and Technology Ventures Risk in the Capital Transformation Process
03/27/2002	George D. Yancopoulos, MD, PhD President, Executive VP and CSO Regeneron Pharmaceuticals Merging Biology with Drug Discovery in Obesity, Inflammation, Angiogenesis, Muscle Disease & Other Setting
03/13/2002	OSI Pharmaceuticals Field trip
03/06/2002	Young Whan Park, PhD Research Fellow Merck Research Laboratories Current Techniques in High Throughput Screening for Drug Discovery Processes
02/27/2002	Jean Denaro, MA Project Manager Pfizer Pharmaceuticals Clinical Research: Methods and Opportunities
02/20/2002	Harmen Bussemaker, PhD Professor ColumbiaUniversity Computational Analysis of Genome Sequences and DNA Microarray Data
02/13/2002	Alex Elbrecht, PhD Research Fellow Merck Research Laboratories Compound Characterization Using Gene Microarrays
02/06/2002	Ron Cohen, MD President, CEO, Founder and Director Acorda Therapeutics So You Want to Start a Biotech Company, Hmmm?
11/28/2001	Jules T. Mitchel, PhD President Target Health, Inc. Principles of Drug Development: a case study in AIDS
11/19/2001	Raymond S. Fersko, JD Mints, Levin, Cohn, Ferris, Glowsky & Pepeo, P.C. Commercializing Biotechnology
10/01/2001	Meirav Chovav, MA, MBA Managing Director Credit Suisse First Boston Biotech, A Business Built on Science
04/25/2001	Shubha Govind, PhD Professor City College, City University of New York, Drug Development Using Flies and Model Organisms
04/18/2001	Conrad Gilliam, PhD Professor Columbia GenomeCenter Identification of Genetic Loci of Human Diseases
04/11/2001	Bernie Yurke, PhD Lucent Technologies Assembling Nanostructures and Nanomotors out of DNA
04/04/2001	Rene Hen, PhD Professor Columbia University Department of Pharmacology Animal Models for Diseases
03/28/2001	Robert Pearlman, Esq. Intellectual Property Causes Patenting
03/21/2001	Stuart Fischer, PhD Research Scientist Columbia GenomeCenter High Through-put Physical Mapping
03/07/2001	Juergen Hammer, PhD Hoffmann-La Roche Inc. Gene Chips and Applications
02/28/2001	Victor Lin , PhD ColumbiaUniversity Irvin CancerCenter Transgenic Mice Facilities
02/21/2001	James Russo, PhD Research Scientist Columbia University Columbia Genome Center The Human Genome Project, Genome Sequencing, and Disease Gene Discovery
02/14/2001	Chris Adams Founder and President Mosaic Technologies Entrepreneurship in Biotech Industry
02/07/2001	Eric Schon, PhD Professor Columbia University Department of Genetics and Development Molecular Genetics of Human Mitochondrial Disease
01/31/2001	Cy Stein, MD Professor Columbia University Department of Medicine Theory and Practice of the Antisense Biotechnology
01/24/2001	Donald Landry, MD Professor Columbia University Department of Medicine Anti-cocaine Catalytic Antibodies
01/17/2001	Arthur Bank, MD Professor Columbia University Department of Medicine On the Road to Hematopoietic Stem Cell Gene therapy